Multiple Myeloma Research Foundation (MMRF)Launches CureCloud™ to Advance Precision Medicine
The MMRF CureCloud will be the first and most comprehensive data hub in multiple myeloma designed to speed the delivery of precision-based treatment to every patient
Norwalk, Conn., June 12, 2019 – The Multiple Myeloma Research Foundation (MMRF) announced today that it is launching the MMRF CureCloud™, a centralized data hub that generates, aggregates and visualizes data to accelerate the delivery of precision medicine to multiple myeloma patients. The CureCloud is a critical part of the organization’s bold three-year plan, which is to transform patient care through addressing the medical industry’s biggest challenge: data sharing and collection.
The MMRF is working with Broad Genomics, Broad Data Science Platform, COTA, Inc., Tempus, EMSI Health, Prometheus Research, LLC, and PierianDx to address a fundamental, and complex, challenge in healthcare that is often overlooked—the need for shared, comprehensive data to identify targets and inform data-driven treatment decisions for multiple myeloma patients. Given that multiple myeloma is a highly heterogeneous disease, substantial amounts of genomic, immune and clinical data needs to be curated and shared across physicians, researchers and patients to drive more effective treatments.
“One of the biggest problems that exists within today’s healthcare system is lack of access to significant quantities of high-quality longitudinal patient data. As a patient-founded and focused organization, we are committed to making the changes needed to transform the healthcare system and find ways to empower patients so that they can make informed decisions about their care,” says Kathy Giusti, Co-Founder and Chief Mission Officer of the MMRF. “One of the first steps in achieving this goal is to take on the near-impossible task of bringing together genomic data, immune data, and electronic health records across a wide variety of patients to create CureCloud.”
The CureCloud model will include the MMRF’s landmark CoMMpassSM study, the largest genomic dataset in any cancer, which identified 12 unique sub-types within myeloma, as well as other MMRF legacy assets and external data sources. Patient data will be de-identified and securely stored.
The MMRF will provide access to this data to every stakeholder in the multiple myeloma ecosystem. A suite of analytics and visualization tools will enable patients and their doctors to compare clinical and genomic data with patients in the CureCloud to help inform treatment decisions, and researchers to identify new targets and generate hypotheses.
“Creating this standards-based, fully-linked, unified data hub that drives data to knowledge, knowledge to insights, and insights to value, will be answering the most critical clinical questions while supporting the identification of new targets and care pathways. This is an exceptionally complex and demanding goal,” says Steve Labkoff, MD, FACP, FACMIA, Chief Data Officer of the MMRF. “It is thanks to the willingness of our partners and the MMRF’s legacy data assets that we are able to collect and aggregate massive amounts of research and clinical data, building one of the most comprehensive and complex systems I have ever seen.”
“Prometheus is very proud to be supporting this ambitious and exciting endeavor by MMRF.” declared Leon Rozenblit, Founder and CEO of Prometheus Research. “I think the CureCloud data hub approach points the way to how valuable data assets about specific diseases will be created in the future. This direction has great promise and will benefit patients for years to come.”
Later this fall, the MMRF will launch a patient registry in which patients will be invited to contribute their clinical and genomic, and eventually immune data, to the CureCloud which will provide further insights and help inform data-driven decisions. This research initiative is currently being piloted with a limited number of patients.
ABOUT Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,770 adults (16,400 men and 14,730 women) in the United States will be diagnosed with MM in 2019 and an estimated 12,770 people are predicted to die from the disease. The five-year survival rate for MM is approximately 47%, versus 31% in 1999.
About the Multiple Myeloma Research Foundation (MMRF)
A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 10 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immune-oncology, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
ABOUT PROMETHEUS | RESEARCH
Prometheus Research is the principal informatics partner to renowned health organizations engaged in ambitious translational research endeavors and quality improvement initiatives. Our agile data platform, RexRegistry, empowers our partners to acquire, integrate, and repurpose disparate sources of health data to accelerate scientific discovery and patient access to new therapies. Together with our consulting services, Prometheus helps forward-thinking institutions build data assets today that will continue advancing the state of care for generations to come.
To learn more about Prometheus’ solutions for rare disease advocacy, please visit our solutions page.